Random Forest Analysis of Out-of-Pocket Health Expenditures Associated with Cardiometabolic Diseases, Lifestyle, Lipid Profile, and Genetic Information in São Paulo, Brazil DOI Open Access
Jean Michel Rocha Sampaio Leite, Lucas Akio Iza Trindade, Jaqueline Lopes Pereira

et al.

Healthcare, Journal Year: 2024, Volume and Issue: 12(22), P. 2275 - 2275

Published: Nov. 14, 2024

There is a lack of empirical studies out-of-pocket health expenditures associated with dyslipidemias, which are major cardiovascular risk factors, especially in underrepresented admixed populations. The study investigates associations costs lipid traits, GWAS-derived genetic scores (GRSs), and other cardiometabolic factors.

Language: Английский

The Inflation Reduction Act Expands Prescription Drug Affordability DOI Creative Commons
Jimmy Zheng, Alexander T. Sandhu

Journal of the American College of Cardiology, Journal Year: 2023, Volume and Issue: 81(21), P. 2112 - 2114

Published: May 1, 2023

Language: Английский

Citations

2
The Inflation Reduction Act and Access to Heart Failure Therapies: Prices, Progress and Promise DOI
Andrew S. Oseran, Rishi K. Wadhera

Journal of Cardiac Failure, Journal Year: 2024, Volume and Issue: 30(12), P. 1657 - 1658

Published: May 19, 2024

Language: Английский

Citations

0
Tafamidis and the Paradox of Rare Disease Therapies DOI Creative Commons

Sérgio Renato da R. Decker,

Dhruv S. Kazi

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(9), P. e2427219 - e2427219

Published: Sept. 13, 2024

Language: Английский

Citations

0
Trends in Healthcare Expenditures and Incremental Healthcare Cost in Adults with Atrial Fibrillation in the United States DOI Creative Commons
Frans Serpa,

Archana Tale,

Peter Zimetbaum

et al.

Heart Rhythm O2, Journal Year: 2024, Volume and Issue: 6(1), P. 11 - 20

Published: Oct. 21, 2024

Atrial fibrillation (AF) is associated with increased health care costs; however, comprehensive data on the financial burden of AF remain limited. The purpose this study was to delineate expenditures among patients AF. We used longitudinal panels from Medical Expenditure Panel Survey covering 2016-2019 estimate identified individuals 18 years and older in first year each panel (2016-2018) by using International Classification Disease, Tenth Revision codes. Covariates included sociodemographic characteristics comorbidities. Health were derived second (2017-2019) reflect cost having condition for an entire year. Adjusted mean annual costs calculated, including total expenditure, hospital inpatient, emergency department visits, office-based outpatient home prescribed medicines, other expenses. models incremental weighted population 3,080,055 adults (382 respondents; age 71.5; 89.9% white). adjusted totaled $14,083 (95% confidence interval $10,887-$17,279) compared $8771 $8106-$9436) those without primary drivers over time inpatient care, medications. $5312 per adult (in 2019 U.S. dollars). Adults United States face a higher across various services than do condition, consistently increasing expenses medicines. Further research needed identify independent contribution these costs.

Language: Английский

Citations

0
The Price of ED: Annual Out of Pocket Cost Disparities of Erectile Dysfunction Medications DOI Creative Commons
Aaron Gurayah, Manish Kuchakulla,

Robert O. Fisch

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 24, 2024

Abstract Our objective was to understand the out-of-pocket (OOP) annual costs for PDE5-I treat erectile dysfunction (ED) through traditional Medicare Part D drug coverage programs and other popular discount programs. We collected data on OOP ED medications from four different sources: D, GoodRx, Mark Cuban Cost Plus Drug Company (MCCPDC), Amazon Pharmacy. compared cost of lowest highest routinely prescribed dosage Sildenafil, Tadalafil, Vardenafil. examined under at 1) hospital retail pharmacies (using twelve zip codes encompassing areas with comprehensive urologic oncology centers) 2) three most prevalent commercial (CVS, Walgreens, Walmart). These findings were platforms GoodRx (via CVS, Walmart), MCCPDC, Pharmacy using R (V4.1.1). For Sildenafil 20mg, including hospitals comparable ranging $1 024-$1 098. The cheaper, $82-$275. 100mg, hospital-based had a median price 446, whereas ranged $22 528-$22 542. Discount preferred $89-$324. Tadalafil 2.5mg, groups $4 721-$4 759. this via much lower, $82-$312. $25 210-$25 235. reported have lower $103-$496. Vardenafil $19 015-$19 039 $86-418 platforms. both sildenafil dosages tadalafil dosages, MCCPDC affordable option. There are significant cost-savings when utilizing options should be presented patients help improve accessibility compliance ED.

Language: Английский

Citations

0
CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks DOI Creative Commons
Julie A. Patterson, Tyler Wagner, Rizgar Ahmed Salih

et al.

PharmacoEconomics - Open, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

The US Centers for Medicare and Medicaid Services (CMS) held patient-focused listening sessions in Fall 2023 each of the first ten drugs selected Inflation Reduction Act's (IRA) Drug Price Negotiation Program (DPNP). This study aimed to quantitatively describe speaker input at sessions, including absolute relative time allocated key areas interest DPNP.

Language: Английский

Citations

0
President's page: The impact of the inflation reduction act on cardiovascular disease prevention DOI Creative Commons
Martha Gulati

American Journal of Preventive Cardiology, Journal Year: 2023, Volume and Issue: 15, P. 100591 - 100591

Published: Sept. 1, 2023

Language: Английский

Citations

1
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis DOI
Kannu Bansal, Vidit Majmundar, Grant M. Young

et al.

JACC Heart Failure, Journal Year: 2024, Volume and Issue: 12(10), P. 1791 - 1793

Published: Aug. 7, 2024

Language: Английский

Citations

0
The Inflation Reduction Act and Patient Costs for Drugs to Treat Heart Failure DOI Creative Commons
Erin Trish,

Karen Van Nuys,

Joanne Wu

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(10), P. e2441915 - e2441915

Published: Oct. 29, 2024

This cross-sectional study examines the pre–Inflation Reduction Act out-of-pocket burden on Medicare patients taking dapagliflozin, empagliflozin, and sacubitril/valsartan.

Language: Английский

Citations

0
A Costly Cure: Understanding and Addressing Financial Toxicity in Cardiovascular Disease Health Care Within the Domain of Social Determinants of Health DOI

Vijay Aaroha Kandula,

Grace L. Smith, Ravi Rajaram

et al.

Methodist DeBakey Cardiovascular Journal, Journal Year: 2024, Volume and Issue: 20(5), P. 15 - 26

Published: Jan. 1, 2024

Cardiovascular disease (CVD) represents a significant financial burden on patients and families, compounded by both direct indirect healthcare costs. The increasing prevalence of CVD, coupled with the rising costs treatment, exacerbates toxicity-defined as economic strain associated physical, emotional, behavioral consequences patients. This review explores scope toxicity in CVD care, detailing its prevalence, risk factors, complex interplay social determinants health such income, insurance status, comorbidities. Drawing from models oncology, we highlight key interventions aimed at mitigating toxicity, including patient counseling, navigation, enhanced patient-physician cost discussions. By adopting these approaches, providers can better support managing their well-being, potentially improving clinical outcomes. Future research is needed to develop standardized assessment tools for implement system-wide mitigation strategies.

Language: Английский

Citations

0